» » »

Prostate Cancer Screening Rye NY

Prostate cancer screening consists of diagnostic tests that can assist with early detection of prostate cancer. Screening may involve a digital rectal exam, prostate-sspecific antigen (PSA) blood test, or a transrectal ultrasound. See below to learn more and to gain access to qualified oncologists in Rye, NY who provide prostate cancer screening.

Steven Edward Vogl
(718) 519-7774
2220 Tiemann Ave
Bronx, NY
Norman Lester Rosen
(914) 965-2060
3333 Henry Hudson Way
Bronx, NY
Richard G Stock MD
(212) 241-7502
1184 5th Ave
New York, NY
Michael Anthony Contillo, MD
914-668-7337
17 Ellis Dr
White Plains, NY
Abraham Mittelman
(914) 681-0025
311 North St
White Plains, NY
Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
Michelle Kristine Miller, MD
914-934-9739
100 Midland Ave
Port Chester, NY
Valiere Alcena
(914) 682-8020
37 Davis Ave
White Plains, NY
Abraham Mittelman, MD
914-681-0025
311 North St Ste 304
White Plains, NY
Data Provided by:
   

All about the PSA Test

The PSA (Prostate-Specific Antigen) test is one of two primary screening tools for prostate cancer. This simple blood test measures the level of PSA, a protein produced in the prostate, present in a man's body. Men typically have an initial PSA screening at 50, or earlier if there's a family history of prostate cancer.

Physicians measure PSA in nanograms per milliliter. An elevated PSA doesn't diagnose cancer and doesn't mean a man has prostate cancer; it just suggests further evaluation. Other medical conditions can also raise PSA levels. A PSA test and additional diagnostic tools help detect small tumors, however, experts say it does not necessarily reduce a man's chance of dying of prostate cancer.

An increase in PSA is the strongest single predictor of prostate cancer risk, and a high PSA score followed by a lower PSA score is not uncommon, even in men who do have cancer. However, PSA progression does predict poor overall survival rates in men with mestacized prostate cancer (meaning it has spread beyond the prostate). The PSA test is actually a better predictor of prostate cancer risk in African-American men with family histories compared to European- American men.

There is controversy over the value of PSA screenings. This spring, researchers released the results of a large-scale study that began in 1992 to evaluate whether or not the PSA test benefited men. In the subsequent media coverage of the results, the news varied widely depending on who was doing the reporting...

Click here to read more from Quality Health